STERIS Reports Strong Revenue Growth and Updated Fiscal Outlook
STERIS Reports First Quarter Financial Results
STERIS plc (NYSE: STE) has shared impressive financial results for its first quarter of fiscal 2026, showing resilience amidst challenges in the market. The company has successfully navigated through economic headwinds with a reported revenue increase of 9%, reaching $1.4 billion.
Revenue and Earnings Performance
In the first quarter of fiscal 2026, STERIS's total revenue from continuing operations experienced a remarkable growth, climbing from $1.3 billion in the prior year to $1.4 billion. The constant currency organic revenue growth was recorded at 8%, reflecting the company's strong operational management.
Impressive Earnings Results
The company has reported a net income from continuing operations of $177.4 million, equating to $1.79 per diluted share. This is an increase from the previous year's figure of $139.8 million or $1.41 per diluted share.
Segment-wise Performance Overview
Each of STERIS's segments showcased resilient growth during the quarter. The Healthcare segment reported revenues of $974.7 million, an increase of 8% from last year. This growth was supported by a 13% rise in service revenue, alongside improvements in capital equipment and consumable revenues.
Applied Sterilization Technologies Growth
The Applied Sterilization Technologies (AST) segment witnessed substantial revenue growth of 13%, reaching $281.2 million. The driving force behind this growth included a notable 46% increase in capital equipment revenue, demonstrating strong market demand.
Life Sciences Performance Metrics
Life Sciences revenue increased by 5%, totaling $135.2 million. This section primarily benefited from an uptick in consumable revenue and showcased improvements in operational profitability.
Robust Cash Flow Generation
Another strong point in STERIS's financial performance is the significant cash flow generated. The net cash provided by operations reached $420 million, a substantial rise from the previous $303.7 million. In addition, free cash flow surged to $326.5 million, marking an increase from $195.7 million year-over-year.
Board Changes and Corporate Developments
In recent corporate governance news, STERIS announced changes to its Board following its annual meeting. The company welcomed Louis Shapiro to the Board while thanking retiring members for their service. These changes are aimed at enriching the Board’s perspectives, particularly in healthcare leadership.
Updated Fiscal Year 2026 Outlook
STERIS has updated its revenue growth forecast for the fiscal year 2026. The company now anticipates a revenue increase from continuing operations of 8-9%, up from earlier projections of 6-7%. This revision is driven by a favorable foreign currency outlook, which is expected to enhance revenue generation.
Expectations and Future Outlook
The management’s outlook for adjusted earnings per diluted share remains unchanged, projecting a range between $9.90 and $10.15. However, anticipated tariffs and healthcare costs may pose challenges to these expectations, indicating a need for continued optimization.
Investor Engagement and Conference Call
STERIS plans to hold a conference call to discuss these results and the company's future direction. Investors are encouraged to engage and listen, whether live or via the replay, which will be made available shortly after the call.
About STERIS
STERIS is at the forefront of providing innovative solutions for patient care, focusing significantly on infection prevention. The company is committed to creating a healthier and safer world through its extensive range of healthcare and life sciences services.
Company Contact Information
For more inquiries, interested parties can contact Julie Winter, Vice President, Investor Relations and Corporate Communications at Julie_Winter@steris.com.
Frequently Asked Questions
What are STERIS's recent financial results?
STERIS reported a 9% revenue growth in the first quarter of fiscal 2026, totaling $1.4 billion and a net income of $177.4 million.
How did the various segments perform?
The Healthcare segment grew 8%, AST saw a 13% rise, and Life Sciences reported a 5% increase in revenue.
What is STERIS's outlook for fiscal 2026?
The company expects revenue growth of 8-9%, revising its expectations based on improved foreign currency rates.
Who were the recent changes in the Board of Directors?
Steris appointed Louis Shapiro to the Board and thanked retiring members Dr. Jaqueline Kosecoff and Dr. Richard Steeves for their service.
How can I listen to the conference call?
The conference call can be accessed at STERIS's investor relations website or via phone. A replay will also be made available afterward.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.